The intersection of genomics and dermatology is opening exciting new possibilities for personalized skin care — moving beyond generic skincare advice to treatments and routines tailored to your unique genetic profile. We spoke with Dr. Debasmita Chakraborty, a dermatologist with expertise in genomic approaches to skin health, about what this means for patients.
How Is Genomics Changing Dermatology?
"Genomics is fundamentally changing how we think about skin health," says Dr. Chakraborty. "For decades, dermatology has relied on clinical observation and trial-and-error. We'd try one treatment, see if it worked, and move to the next if it didn't. Genomics allows us to understand why a patient's skin behaves the way it does — and to predict which treatments are most likely to work for their specific genetic profile."
She points to several areas where genomics is already making a clinical difference: psoriasis treatment selection, melanoma risk assessment, pharmacogenomics for dermatological medications, and personalized skincare recommendations based on genetic skin traits.
Which Skin Conditions Have the Strongest Genetic Components?
"Psoriasis and atopic dermatitis (eczema) are among the most genetically complex skin conditions," Dr. Chakraborty explains. "Psoriasis has a heritability of approximately 60–90% — meaning genetics accounts for the majority of disease risk. We've identified over 80 genetic loci associated with psoriasis, many of which are in immune regulation genes."
For eczema, filaggrin (FLG) gene mutations are the strongest known risk factor — present in approximately 30% of eczema patients. "Knowing a patient has FLG mutations tells me their skin barrier is compromised, and I'll prioritize barrier repair with ceramide-rich moisturizers and avoid anything that further disrupts the barrier."
Melanoma has a significant hereditary component, with CDKN2A mutations causing familial melanoma syndrome. "For patients with a family history of melanoma, genetic testing can identify those at highest risk who need intensive surveillance and sun protection."
What About Pharmacogenomics in Dermatology?
"This is an area where genomics is already changing clinical practice," she says. "Thiopurine methyltransferase (TPMT) testing before azathioprine therapy is now standard — patients with TPMT deficiency are at risk of severe bone marrow suppression at standard doses. HLA-B*5801 testing before allopurinol is recommended in Asian populations because of the high risk of severe cutaneous adverse reactions in carriers."
She also discusses the emerging role of pharmacogenomics in biologic therapy selection for psoriasis. "We're beginning to identify genetic predictors of response to specific biologics — which could help us choose the right biologic for the right patient from the start, rather than cycling through multiple agents."
What Can Patients Do with Genetic Skin Information?
"The most actionable information for most patients is around skin aging, UV sensitivity, and barrier function," Dr. Chakraborty advises. "If you know you have variants associated with faster collagen breakdown, you start retinoids earlier and are more rigorous about sun protection. If you have FLG variants, you prioritize barrier repair. If you have MC1R variants associated with high UV sensitivity, you're even more vigilant about SPF."
She emphasizes that genetic information should complement, not replace, clinical assessment. "Your genes set the predisposition, but your lifestyle, environment, and skincare habits determine the outcome. Genomics gives you the map — you still have to make the journey."
Your Skin Is Genetically Unique — Your Routine Should Be Too
BeautyMap by MapmyGenome is India's first DNA-based skin and hair health test — revealing your genetic collagen profile, UV sensitivity, hydration needs, and skin condition risk so you can build a truly personalized skincare routine.
